Piper Sandler reiterated its stock rating for Tenax Therapeutics ahead of the company's upcoming trial. The specific rating was not disclosed.
Piper Sandler's reiteration of its rating on Tenax Therapeutics stock comes as the company approaches a significant upcoming trial. This action suggests the firm's continued confidence in the company's prospects.
Piper Sandler's reiteration of its rating on Tenax Therapeutics stock comes as the company approaches a significant upcoming trial. This action suggests the firm's continued confidence in the company's prospects.
Pick the topics you care about. Get only what matters, on your cadence.
Market Quick Take – Weak euro in focus - 05 October 2026home.saxoTrading stocks, CFDs, spread betting, futures, and options involves a high level of risk and may not be suitable for all investors. Prices can move rapidly, and losses can occur quickly and exceed your expectations.
